ESR1 and breast cancer: Although the addition of tamoxifen markedly improved recurrence-free survival at 15 years follow-up from 65% to 78% in the NSABP B-14 study of women with ER+ early breast cancer, many of these patients did not benefit from tamoxifen [10].